Imunon (IMNN) Projected to Post Quarterly Earnings on Thursday

Imunon (NASDAQ:IMNN) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Imunon to post earnings of ($1.54) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Imunon Price Performance

IMNN opened at $3.22 on Thursday. The company has a market capitalization of $9.89 million, a price-to-earnings ratio of -0.33 and a beta of 2.14. Imunon has a 1-year low of $2.99 and a 1-year high of $41.22. The business has a 50 day moving average price of $3.56 and a two-hundred day moving average price of $4.62.

Hedge Funds Weigh In On Imunon

A hedge fund recently bought a new stake in Imunon stock. Armistice Capital LLC bought a new stake in Imunon, Inc. (NASDAQ:IMNN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned approximately 8.69% of Imunon as of its most recent SEC filing. 4.47% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IMNN has been the subject of several research analyst reports. Brookline Capital Acquisition restated a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $232.50.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.